1. Management of hypertension in patients with chronic kidney disease
Matthew Weir 
Journal of Indian College of Cardiology 
Volume 5, Pages S43-S48 (March 2015)
DOI: /j.jicc
Copyright © Terms and Conditions

2. Fig. 1 The glomerular apparatus of the kidney.
Journal of Indian College of Cardiology 2015 5, S43-S48DOI: ( /j.jicc )
Copyright © Terms and Conditions

3. Fig. 2 Relationship of renal damage to blood pressure.
Journal of Indian College of Cardiology 2015 5, S43-S48DOI: ( /j.jicc )
Copyright © Terms and Conditions

4. Fig. 3
Estimated mean decline in glomerular filtration rate (GFR) from baseline to selected follow-up times in MDRD (Continuous line: BP125/75, dashed line: BP 140/90).
Source: Peterson JC, et al. Annals of Internal Medicine 1995;123: 754–762
Journal of Indian College of Cardiology 2015 5, S43-S48DOI: ( /j.jicc )
Copyright © Terms and Conditions

5. Fig. 4
Proportion of patients with end-stage renal disease in each study arm.
Source: Ruggenenti, P. et. Al, Lancet 2005; 365–939–46
Journal of Indian College of Cardiology 2015 5, S43-S48DOI: ( /j.jicc )
Copyright © Terms and Conditions

6. Fig. 5
Cumulative incidence of the composite primary outcome, According to baseline proteinuria status.
Source: Appel LJ et al. N Engl J Med 2010; 363:918–929
Journal of Indian College of Cardiology 2015 5, S43-S48DOI: ( /j.jicc )
Copyright © Terms and Conditions

7. Fig. 6
Relative risk for kidney disease progression (based on current level of systolic blood pressure and current urine protein excretion).
Source: Jafar TH, et al. Ann Intern Med 2003; 139: 244–252
Journal of Indian College of Cardiology 2015 5, S43-S48DOI: ( /j.jicc )
Copyright © Terms and Conditions

8. Fig. 7
Impact of quartile of achieved mean systolic blood pressure on time to renal endpoint.
Source: Pohl MA, et. al. J Am Soc Nephrol 2005; 16: 3027–3037
Journal of Indian College of Cardiology 2015 5, S43-S48DOI: ( /j.jicc )
Copyright © Terms and Conditions

9. Fig. 8
Natural log of the relative risk for reaching a renal endpoint by level of achieved follow-up SBP.
Source: Pohl MA, et. al. J Am Soc Nephrol 2005; 16: 3027–3037
Journal of Indian College of Cardiology 2015 5, S43-S48DOI: ( /j.jicc )
Copyright © Terms and Conditions

10. Fig. 9 Differences in endpoint outcomes in two groups of REIN-2 trial.
Source: Ruggenenti P et al Lancet. 2005; 365: 939–946
Journal of Indian College of Cardiology 2015 5, S43-S48DOI: ( /j.jicc )
Copyright © Terms and Conditions

11. Fig. 10 CV event rates and mortality in AASK.
Source: Wright, JT Jr, JAMA. 2002; 288: 2421–2431
Journal of Indian College of Cardiology 2015 5, S43-S48DOI: ( /j.jicc )
Copyright © Terms and Conditions

12. Fig. 11
Hazard ratio for cardiovascular and heart failure end points as functions of percent change in month-6 albuminuria.
Source: De Zeeuw et al; Circulation. 2004;110:921–927
Journal of Indian College of Cardiology 2015 5, S43-S48DOI: ( /j.jicc )
Copyright © Terms and Conditions